Production Capacity Integration + Energy Independence, Blue Sail Medical's Glove Business Turnaround Expected

Recently, Blue Sail Medical (002382.SZ) announced that two key acquisitions by its subsidiary, Shandong Blue Sail Health Technology Co., Ltd. (“Shandong Health Tech”), have been successfully completed. The company has acquired 100% equity in Zibo Blue Sail Health Tech Co., Ltd. and Zibo Blue Sail Protective Products Co., Ltd. (“Zibo Health Tech, Zibo Protective”), as well as secured an 80% stake in Zibo Hongda Thermal Power Co., Ltd. (“Hongda Thermal Power”). These projects work synergistically to achieve dual breakthroughs: integrating glove production capacity and offsetting energy costs. This provides strong momentum for a turnaround in Blue Sail Medical’s core glove business, with ongoing performance flexibility expected to be released.

According to the announcement, both acquisitions were facilitated by a $200 million capital increase from a Thai industrial investor, which did not utilize Blue Sail Medical’s own funds, alleviating cash flow pressure and enabling precise business upgrades. Shandong Health Tech acquired Zibo Health Tech and Zibo Protective for 800 million yuan, aiming to revitalize nitrile glove resources, transforming the industry’s supply-demand imbalance from “new capacity addition” to “resource integration,” thereby improving operational efficiency and boosting overall competitiveness and profitability of the nitrile glove business. After the transaction, Shandong Health Tech will centrally manage all of Blue Sail Medical’s nitrile glove resources, forming three production bases with an annual capacity of approximately 25 billion gloves. The unified management of health protection products will create synergies in equipment deployment, process optimization, and supply chain management, with operational efficiency expected to continue improving.

Alongside capacity integration, addressing energy supply shortages has become another key breakthrough. Shandong Health Tech acquired an 80% stake in Hongda Thermal Power for 400 million yuan, primarily to systematically address energy supply gaps at Zibo’s nitrile glove manufacturing base and establish an independent, controllable energy security system. As the only heat source in its industrial park, it can provide stable, low-cost electricity and heat to Blue Sail’s glove factories. Additionally, thanks to the capital increase from Thailand, Shandong Health Tech obtained a rare combined heat and power (CHP) approval, with related units expected to start operation in Q2 2026, utilizing excess heat from glove production for power generation and grid sales. These positive developments enable the company to implement CHP in both Zibo and Weifang, further expanding cost advantages. The ongoing growth of the glove business will bring additional profit growth points for Blue Sail Medical.

By Q4 2025, the gross profit margin of the glove business has successfully turned positive, and the health protection segment is expected to be the most significant driver of performance recovery in 2026. Currently, the company’s nitrile glove capacity is fully utilized and sold out, while exports of PVC gloves have surged since October 2025, laying a solid foundation for price increases in these two major glove categories.

Amid multiple positive factors, the turnaround of Blue Sail Medical’s glove business is becoming increasingly clear. Currently, under the influence of global geopolitical factors, the prices of core raw materials for gloves have risen sharply, entering a cycle of price increases. Meanwhile, the company’s precise prediction of raw material price trends, through strategic phased procurement and price locking, has effectively locked in raw material costs through the first half of 2026, successfully avoiding cost pressures from this round of raw material price surges.

Furthermore, the company has two unique advantages in raw material security. First, its controlling shareholder’s chemical division is a leading enterprise in plasticizers and resin adhesives nationwide, with annual revenue exceeding 10 billion yuan, and is a major supplier of raw materials for PVC gloves. Second, its Thai industrial investor owns over 200,000 tons of nitrile latex capacity, which can provide reasonably priced and stable nitrile latex resources in extreme market conditions.

Historical experience shows that terminal glove prices tend to increase more than raw material prices, especially in the current industry cleanup and return of pricing power to leading companies. Price increases at the terminal level are more transmissible. The company is expected to leverage its raw material cost-locking advantage to fully benefit from industry-wide price hikes, achieving rapid profit recovery.

Meanwhile, the company’s glove production line upgrades are progressing in phases. The Weifang plant completed its upgrade when first investing in Thailand in 2024, reaching advanced standards; by the end of 2025, both Zibo bases will have completed upgrades, significantly improving production efficiency and cost control. By reducing energy costs through acquisitions of thermal power plants and upgrading production lines, combined with industry recovery opportunities, there remains substantial room for gross profit margin improvement, potentially leading to unexpected performance growth for Blue Sail Medical.